---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-019840"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:22:30.655357+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DiaMedica identifies cause of DM199 clinical hold; plans FDA resubmission in Sep

## Summary
- Clinical hold cause: DM199 protein bound to prior IV bag, reducing dose; new bag delivered higher dose, causing hypotension.
- Will submit revised protocol to FDA in September requesting removal of clinical hold; FDA has 30 days to respond.
- Cash and investments $38.4M as of June 30, 2022; cash runway into 2024.
- R&D expenses $2.0M in Q2 2022 vs $2.2M Q2 2021; net cash used in ops $6.4M for six months.
- REDUX CKD trial close-out ongoing; company maintains focus on acute ischemic stroke program.

## SEC filing metadata
- accession: 0001437749-22-019840
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/0001437749-22-019840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774922019840/dmtp20220810_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-019840
- JSON: https://secwatch.observer/filing/0001437749-22-019840.json
- Plain text: https://secwatch.observer/filing/0001437749-22-019840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.